High-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: a retrospective study of 25 Chinese patients

AIM: To evaluate the efficacy and safety of ruthenium-106 (106Ru) plaque radiotherapy at a dose (>50 Gy) higher than recommended (29-50 Gy) for treatment of circumscribed choroidal hemangioma (CCH) in Chinese patients. METHODS: This retrospective study included 25 symptomatic CCH patients underg...

Full description

Bibliographic Details
Main Authors: Jing Li, En-Zhong Jin, Jian-Hong Liang
Format: Article
Language:English
Published: Press of International Journal of Ophthalmology (IJO PRESS) 2020-03-01
Series:International Journal of Ophthalmology
Subjects:
Online Access:http://www.ijo.cn/gjyken/ch/reader/view_abstract.aspx?file_no=20200309&flag=1
id doaj-8a346f2b6c1a441ea90232a31b3cc9a6
record_format Article
spelling doaj-8a346f2b6c1a441ea90232a31b3cc9a62020-11-25T02:04:02ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982020-03-0113342543010.18240/ijo.2020.03.09High-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: a retrospective study of 25 Chinese patientsJing Li0En-Zhong Jin1Jian-Hong Liang2Department of Ophthalmology, Ophthalmology and Optometry Center, Peking University People’s Hospital and Beijing Key Laboratory of Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing 100044, China; Department of Ophthalmology, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaanxi Province, ChinaDepartment of Ophthalmology, Ophthalmology and Optometry Center, Peking University People’s Hospital and Beijing Key Laboratory of Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing 100044, ChinaDepartment of Ophthalmology, Ophthalmology and Optometry Center, Peking University People’s Hospital and Beijing Key Laboratory of Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing 100044, ChinaAIM: To evaluate the efficacy and safety of ruthenium-106 (106Ru) plaque radiotherapy at a dose (>50 Gy) higher than recommended (29-50 Gy) for treatment of circumscribed choroidal hemangioma (CCH) in Chinese patients. METHODS: This retrospective study included 25 symptomatic CCH patients undergoing 106Ru plaque brachytherapy involving 25 eyes between January 2005 and August 2016. Ophthalmic examination was performed at the baseline and at each post-treatment follow-up visit, using best-corrected visual acuity (BCVA), dilated fundus examination, and B-scan ultrasonography. The primary efficacy outcome measures included the changes in BCVA and hemangioma dimensions at the last followup visit from the baseline. RESULTS: The mean follow-up duration was 28.0±26.6 (range, 12-110)mo. All the hemangiomas were located in the posterior pole except for two involving the fovea. The mean apex dose of 106Ru plaque radiotherapy was 84.4±19.7 Gy. The mean BCVA improved from 41.4±29.3 (0-97) at the baseline to 53.0±33.8 (0-97) ETDRS letters at the last visit (P=0.01). The mean hemangioma height declined from 3.98±0.88 (2.40-5.50) mm to 0.84±1.63 (0-6.47) mm (P≤0.001), and the greatest linear diameter (GLD) reduced from 9.36±2.23 (6.80-15.00) to 7.40±2.45 (0-13.00) mm (P≤0.001). Hemangioma size increased in one (4%) eye with a worsened vision, and subretinal fluid completely resolved in all but one patient (4%). Radiation-related retinopathy was observed in two patients at post-treatment 9 and 11mo, respectively. CONCLUSION: 106Ru plaque brachytherapy at a dose (>50 Gy) higher than recommended (29-50 Gy) is an effective treatment regimen for symptomatic CCH associated with significantly improved visual acuity and a favorable safety profile in Chinese patients.http://www.ijo.cn/gjyken/ch/reader/view_abstract.aspx?file_no=20200309&flag=1circumscribed choroidal hemangiomaradiotherapyruthenium-106chinese patientsretrospective study
collection DOAJ
language English
format Article
sources DOAJ
author Jing Li
En-Zhong Jin
Jian-Hong Liang
spellingShingle Jing Li
En-Zhong Jin
Jian-Hong Liang
High-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: a retrospective study of 25 Chinese patients
International Journal of Ophthalmology
circumscribed choroidal hemangioma
radiotherapy
ruthenium-106
chinese patients
retrospective study
author_facet Jing Li
En-Zhong Jin
Jian-Hong Liang
author_sort Jing Li
title High-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: a retrospective study of 25 Chinese patients
title_short High-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: a retrospective study of 25 Chinese patients
title_full High-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: a retrospective study of 25 Chinese patients
title_fullStr High-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: a retrospective study of 25 Chinese patients
title_full_unstemmed High-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: a retrospective study of 25 Chinese patients
title_sort high-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: a retrospective study of 25 chinese patients
publisher Press of International Journal of Ophthalmology (IJO PRESS)
series International Journal of Ophthalmology
issn 2222-3959
2227-4898
publishDate 2020-03-01
description AIM: To evaluate the efficacy and safety of ruthenium-106 (106Ru) plaque radiotherapy at a dose (>50 Gy) higher than recommended (29-50 Gy) for treatment of circumscribed choroidal hemangioma (CCH) in Chinese patients. METHODS: This retrospective study included 25 symptomatic CCH patients undergoing 106Ru plaque brachytherapy involving 25 eyes between January 2005 and August 2016. Ophthalmic examination was performed at the baseline and at each post-treatment follow-up visit, using best-corrected visual acuity (BCVA), dilated fundus examination, and B-scan ultrasonography. The primary efficacy outcome measures included the changes in BCVA and hemangioma dimensions at the last followup visit from the baseline. RESULTS: The mean follow-up duration was 28.0±26.6 (range, 12-110)mo. All the hemangiomas were located in the posterior pole except for two involving the fovea. The mean apex dose of 106Ru plaque radiotherapy was 84.4±19.7 Gy. The mean BCVA improved from 41.4±29.3 (0-97) at the baseline to 53.0±33.8 (0-97) ETDRS letters at the last visit (P=0.01). The mean hemangioma height declined from 3.98±0.88 (2.40-5.50) mm to 0.84±1.63 (0-6.47) mm (P≤0.001), and the greatest linear diameter (GLD) reduced from 9.36±2.23 (6.80-15.00) to 7.40±2.45 (0-13.00) mm (P≤0.001). Hemangioma size increased in one (4%) eye with a worsened vision, and subretinal fluid completely resolved in all but one patient (4%). Radiation-related retinopathy was observed in two patients at post-treatment 9 and 11mo, respectively. CONCLUSION: 106Ru plaque brachytherapy at a dose (>50 Gy) higher than recommended (29-50 Gy) is an effective treatment regimen for symptomatic CCH associated with significantly improved visual acuity and a favorable safety profile in Chinese patients.
topic circumscribed choroidal hemangioma
radiotherapy
ruthenium-106
chinese patients
retrospective study
url http://www.ijo.cn/gjyken/ch/reader/view_abstract.aspx?file_no=20200309&flag=1
work_keys_str_mv AT jingli highdoseruthenium106plaquetherapyforcircumscribedchoroidalhemangiomaaretrospectivestudyof25chinesepatients
AT enzhongjin highdoseruthenium106plaquetherapyforcircumscribedchoroidalhemangiomaaretrospectivestudyof25chinesepatients
AT jianhongliang highdoseruthenium106plaquetherapyforcircumscribedchoroidalhemangiomaaretrospectivestudyof25chinesepatients
_version_ 1724945033700835328